tretazicar has been researched along with Carcinoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dubois, L; Ehsaan, M; Heap, JT; Knox, R; Kubiak, AM; Kuehne, SA; Lambin, P; Minton, NP; Paesmans, K; Theys, J; Van Mellaert, L | 1 |
| Minton, NP | 1 |
| Gilligan, MG; Green, NK; Kerr, DJ; Mautner, V; McNeish, IA; Mountain, A; Searle, PF; Weedon, SJ; Wrighton, CJ; Young, LS | 1 |
1 review(s) available for tretazicar and Carcinoma
| Article | Year |
|---|---|
Clostridia in cancer therapy.
Topics: Animals; Antineoplastic Agents; Aziridines; Carcinoma; Clostridium; Cytosine Deaminase; Drug Delivery Systems; Humans; Mice; Neoplasms; Nitroreductases; Prodrugs; Spores, Bacterial; Xanthones | 2003 |
2 other study(ies) available for tretazicar and Carcinoma
| Article | Year |
|---|---|
Spores of Clostridium engineered for clinical efficacy and safety cause regression and cure of tumors in vivo.
Topics: Animals; Antineoplastic Agents; Aziridines; Biological Therapy; Carcinoma; Clostridium; Colonic Neoplasms; Mice; Neisseria meningitidis; Nitroreductases; Organisms, Genetically Modified; Plasmids; Prodrugs; Protein Engineering; Spores, Bacterial; Xenograft Model Antitumor Assays | 2014 |
Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Aziridines; Carcinoma; Cell Line; Cell Survival; Cisplatin; Escherichia coli; Female; Genetic Vectors; Humans; Mice; Mice, Inbred BALB C; Nitroreductases; Prodrugs | 2000 |